Articles by Jacques Henri Max Cohen in JoVE
High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment Aymric Kisserli1,2, Thierry Tabary1,2, Jacques Henri Max Cohen1,2, Valérie Duret1,2, Rachid Mahmoudi3,4 1Department of Immunology, Reims University Hospitals, Robert Debré Hospital, 2Faculty of Medicine, LRN EA 4682, University of Reims Champagne-Ardenne, 3Department of Internal Medicine and Geriatrics, Reims University Hospitals, Maison Blanche Hospital, 4Faculty of Medicine, EA 3797, University of Reims Champagne-Ardenne Here, we describe an innovative method to determine complement receptor 1 (CR1) length polymorphisms for use in several applications, particularly the assessment of susceptibility to diseases such as Alzheimer's disease (AD). This method could be useful to better understand the role of CR1 isoforms in the pathogenesis of AD.
Other articles by Jacques Henri Max Cohen on PubMed
Significant Genetic and Antigenic Variability Within the Env Gene of Systemic Human Immunodeficiency Virus Type 1 Group O Populations During the Natural Course of a Heterosexual Infection: a Pilot Study Journal of Clinical Microbiology. Apr, 2007 | Pubmed ID: 17267630 We assessed the genetic and the antigenic variability within the env gene of peripheral blood human immunodeficiency virus (HIV) type 1 (HIV-1) group O populations during the natural course of a female heterosexual infection. Our data revealed the existence of a significant increase in amino acid sequence variability within the C2-V3 and gp41 regions (P = 0.023 and P < 0.001, respectively) in association with substitutions within neutralizing epitope sequences usually selected for HIV serological assays. These antigenic variations might significantly decrease the sensitivity of classical HIV enzyme-linked immunosorbent assays with blood samples of subjects heterosexually infected by HIV-1 group O strains. These findings may be of significant use both to devise diagnostic tools and to pursue suitable therapeutic modalities in cases of heterosexual infection by outlier HIV-1 strains.